WHO Register of non-State actors

Disclaimer:

Information regarding a non-State actor, contained in the section “Non-State Actors Profiles” in the Register, has been provided by that non-State actor itself, and the accuracy and completeness of such information is the sole responsibility of that non-State actor, not WHO. In turn, information in the sections “WHO’s Engagement” and “Non-State Actors in Official Relations” has been provided by WHO, subject to certain conditions. All access and use of any section of the Register is governed by the Terms and Conditions of Use.

Overview

Official name

World Association of Societies of Pathology and Laboratory Medicine

Acronym (if applicable)

WASPaLM

Short self description

A global network of physician-led Societies of Pathology and Laboratory Medicine

Website

http://www.waspalm-association.org

Web link to health relevant activities

Parent entity (if applicable)

The entity you represent is indicated as a parent of the following entities in the Register:

N / A

Date submitted

26 Aug 2024 01:53:28 PM

General information

Name

Official name

World Association of Societies of Pathology and Laboratory Medicine

Acronym (if applicable)

WASPaLM

Commonly used name (if applicable)

WASPaLM

Names in other official languages (if applicable) Name Abbreviation

WASPaLM

Former name

Short self description

A global network of physician-led Societies of Pathology and Laboratory Medicine

Address Contact

Address 1

Via Farini 81 c/o MZ Congressi

Address 2

Address 3

Town/City

Milano

State/Region

ITALY

Postal code

20100

Country

Italy

Email (generic)

roberto.verna@fondazione.uniroma1.it

Related links

Website

http://www.waspalm-association.org

Governance

Legal status

Registered not-for-profit corporation

Year established

1947

Governance structure

Description of main decision making bodies (e.g. board, board of directors, executive board, executive committee, etc).

Name of body

Bureau

Composition and current list of members Name Function Affiliation

Walter Alallon

President

Professor, President of the Board at the Clínicas Hospital, School of Medicine, University of the Republic of Uruguay,

Mariano Bizzarri

Secretary Treasurer

Professor of Clinical Pathology Sapienza University of Rome Italy

Roberto Verna

President Elect

Dept. of Experimental medicine In Unam Sapientiam University of Roma

Augusto Machado

Director Europe

Laboratório de Análises Clínicas e Anatomia Patológica, Lda Laboratory Director

Alberto Zamora

Director North America

Professor of Pathology and Molecular Medicine, and Medicine, McMaster University, Hamilton Canada

Praveen Sharma

Director South East Asia

Professor of Clinical Pathology All India Institute

Flavio Alcantara

Director Latin America

Assistant Professor physician in the Central Laboratory Division “Hospital das Clinicas” U. of São Paulo - Medical School (HC-FMUSP).

Chuanxin Wang

Director Western Pacific

Professor of Shandong University and dean of the Innovative Technology Research Institute of Laboratory Medicine of Shandong University.

Ozkan Alatas

Director Medicerranean Area

Professor of Clinical Biochemistry Director of Clinical Laboratory in Eskisehir Osmangazi University Hospital Turkey

Masami Murakami

Past President

Professor and Director, Dept of Laboratory Medicine. Gunma Univ Tokyo, Japan

Tahir Pillay

Director African Area

Prof Tahir Pillay is Chief Specialist, Professor and Head of Pathology and the department of Chemical Pathology, University of Pretoria

Functions

Management of the Association
Conduct the general business of the Association to promote its purposes

Name of body

Executive Committee

Composition and current list of members Name Function Affiliation

Walter Alallon

President

Director Clinical Pathology Dept CASMU Montevideo Uruguay

Roberto Verna

President Elect

In Unam Sapientiam University of Roma

Mariano Bizzarri

Secretary Treasurer

Sapienza University of Rome

Masami Murakami

Past President

Showa Gunma Univerity Tokyo

Functions

Rules the Management of the Association

General Assembly

Does the entity have a General Assembly of members or a similar body?

Yes

Name

House of Representatives

Composition

Two Members from each Constituent Society

Functions

Advice on policy and programmes of the Association

Financial information

Latest available annual income (month/year)

From

January

2023

December

2023

Annual income (USD)

14,172

Latest available assets (month/year)

As of

December

2023

Total assets (USD)

15,045

Income sources (in USD)

Income source Income type

Private sector entities (including business associations)

Philanthropic foundations

NGOs, academic institutions

Government entities, intergovernmental organizations, including UN

General public, individuals

Total

Sales of goods and services *

8,039

Grants / Donations

In-kind donations

Membership fees

4,868

Investment income

Others

Total

12,907

* income from congresses / conferences should be listed under Sales of goods and services

Additional information

These amounts are approximate and subject to change, with payment of bills.

Membership

Entity's members

Is the entity you represent membership based?

Yes

Overview of categories and their voting rights in the main governing body:

Total number Voting

Individuals

NGOs

Private sector entities

Philanthropic foundations

Academic institutions

Government entities

Intergovernmental organizations

Organizational Structure

Parent entity

In the register Registered Entity Entity Name

No data available

Yes

Legal status

Affiliated entities (or subsidiaries)

In the register Registered Entity Entity Name

No data available

Relations

Entity's membership in other entities

In the register Registered Entity Entity Name Type of membership

No data available

Members of the entity

In the register Registered Entity Member Name

No data available

Activities

Aims (or purposes, objectives) of the entity as they appear in its constitution or by-laws or equivalent document.

1. Extend medical knowledge
2. Further the welfare of the sick
3. Promote public health
More specifically, the purposes of the Association are to promote the practice of pathology and laboratory medicine; the development of all branches of pathology and laboratory medicine, education in pathology and laboratory medicine, and the organization of efficient pathology and laboratory medicine services; and to foster the development of and cooperation among its constituent societies and, thereby, to benefit patients and facilitate the improved understanding of disease throughout the world.

The activities of the entity are related to the following strategic priorities and outcomes of the current WHO's General Programme of Work:

Strategic objective 1: Respond to climate change, an escalating health threat in the 21st century

Joint outcome 1.1. More climate-resilient health systems are addressing health risks and impacts

Joint outcome 1.2. Lower-carbon health systems and societies are contributing to health and well-being

Strategic objective 2: Address health determinants and the root causes of ill health in key policies across sectors

Joint outcome 2.1. Health inequities reduced by acting on social, economic, environmental and other determinants of health

Joint outcome 2.2. Priority risk factors for noncommunicable and communicable diseases, violence and injury, and poor nutrition, reduced through multisectoral approaches

Joint outcome 2.3. Populations empowered to control their health through health promotion programmes and community involvement in decision-making

Strategic objective 3: Advance the primary health care approach and essential health system capacities for universal health coverage

Joint outcome 3.1. The primary health care approach renewed and strengthened to accelerate universal health coverage

Joint outcome 3.2. Health and care workforce, health financing and access to quality-assured health products substantially improved

Joint outcome 3.3. Health information systems strengthened and digital transformation implemented.

Strategic objective 4: Improve health service coverage and financial protection to address inequity and gender inequalities

Joint outcome 4.1. Equity in access to quality services improved for noncommunicable diseases, mental health conditions and communicable diseases, while addressing antimicrobial resistance

Joint outcome 4.2. Equity in access to sexual, reproductive, maternal, newborn, child, adolescent and older person health and nutrition services and immunization coverage improved

Joint outcome 4.3. Financial protection improved by reducing financial barriers and out-of-pocket health expenditures, especially for the most vulnerable

Strategic objective 5: Prevent, mitigate and prepare for risks to health from all hazards

Joint outcome 5.1. Risks of health emergencies from all hazards reduced and impact mitigated

Joint outcome 5.2. Preparedness, readiness and resilience for health emergencies enhanced

Strategic objective 6: Rapidly detect and sustain an effective response to all health emergencies

Joint outcome 6.1. Detection of and response to acute public health threats is rapid and effective

Joint outcome 6.2. Access to essential health services during emergencies is sustained and equitable

Additional information on the entity's activities

To extend medical knowledge;
To further the welfare of the sick & promote public health.
More specifically:to promote the practise of pathology & laboratory medicine & and to promote their development(all branches). by furthering education in pathology and laboratory medicine

Country presence

Countries where the entity has activities, members and regional offices / representatives:

Regions

Countries

Activities

Members

Offices / representatives

African Region

Region of the Americas

Eastern Mediterranean Region

European Region

South-East Asia Region

Western Pacific Region

Global

Disclosure & declaration

Tobacco/Arms related disclosure statement for non-State actors

Pursuant the WHO Framework of Engagement with Non-State Actors, WHO does not engage with the tobacco industry or non-State actors that work to further the interests of the tobacco industry. WHO also does not engage with the arms industry.

For the purposes of this statement:

tobacco industry means any entity involved in the manufacture, sale or distribution of tobacco and related products, and any affiliate of such entity; and
arms industry means any entity involved in the manufacture, sale or distribution of arms, and any affiliate of such entity.

This disclosure statement needs to be provided by any nongovernmental organization, private sector entity, philanthropic foundation and academic institution prior to engaging with WHO.

In view of the foregoing, please answer the following questions:

Is your entity, or was your entity over the last four years, part of the tobacco or arms industries (as defined above)?

Yes

No

Unable to answer

To the best of your entity’s knowledge, is your entity, or has your entity over the last four years, engaged in activities that are aimed at furthering or supporting the interests of the tobacco industry? This includes, but is not limited to, supply contracts, contract work, services and lobbying.

Yes

No

Unable to answer

To the best of your entity’s knowledge, does your entity currently, or did your entity over the last four years, have any other association or relationship with the tobacco industry (as defined above). This includes in particular investment interests (other than general mutual funds or similar arrangements whereby your entity has no control over the selection of the investments), commercial business interests, the provision or receipt of financial and/or other support.

Yes

No

Unable to answer

If you have answered yes to any of the above or are unable to answer one or more questions, please provide a general statement of explanation.

Please note that the WHO Secretariat reserves the right to request additional information from your entity in this regard.

By providing this statement, your entity commits to promptly inform WHO of any change to the above information and to complete a new statement that describes the changes.

Engagement with other industries affecting human health or affected by WHO norm and standards

Does the entity you represent have any formal association, affiliation or links with the following industry sectors?

If yes, please tick the box of the industry concerned and provide details in the space provided:

Alcohol

Chemical

Food and beverages

Health care

WASPaLM is in contact with several Universities, Hostpitals and Research Centers dealing with Health Care

Pharmaceutical

Others

Please specify industry

Industries of In Vitro Diagnostics

Abbott diagnostics; Snibe; Roche diagnostics

WHO Secretariat reserves the right to request additional information from the entity you represent relevant to its engagement with WHO.

*Sexual Exploitation, Abuse and Harassment (SEAH) and Misconduct (abusive or fraudulent)

Entities engaging with WHO are expected to ensure that the conduct of their employees and any other persons engaged by them to perform any activities or to provide any services for WHO on behalf of the entities is consistent with the WHO standards of conduct. In particular, WHO has zero tolerance towards any form of sexual misconduct, which includes sexual exploitation, sexual abuse, sexual violence, and sexual harassment, and other types of abusive or fraudulent conduct. In the view of the forgoing, please confirm that your entity shall:

Take all reasonable and appropriate measures to prevent sexual misconduct as defined in WHO’s Policy on Preventing and Addressing Sexual Misconduct, and other types of abusive or fraudulent conduct as defined, respectively, in WHO’s Policy on Preventing and Addressing Abusive Conduct and in WHO’s Policy on Prevention, Detection and Response to Fraud and Corruption by any of its employees and by any other persons engaged by it to perform any activities or to provide any services for WHO on the entity’s behalf;

Promptly report to WHO’s Office of Internal Oversight Services (IOS) at investigation@who.int any actual or suspected misconduct, as defined by WHO in these Policies and of which the entity becomes aware;

Promptly communicate to IOS any measures that may be necessary or appropriate to protect the confidentiality and wellbeing of the alleged victim;

Promptly respond to any actual or suspected misconduct as defined by WHO in these Policies of which the entity becomes aware; and

To cooperate with IOS and keep IOS informed of the status and outcome of any measures of protection, corrections to operations, investigation, and disciplinary action taken against any perpetrator by the entity.

Date submitted